Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 6,816 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,816 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $93.13, for a total value of $634,774.08. Following the completion of the sale, the chief executive officer now owns 227,710 shares in the company, valued at approximately $21,206,632.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total value of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total value of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $964,178.17.
• On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The shares were sold at an average price of $68.16, for a total value of $133,457.28.

Natera Price Performance

Shares of Natera stock traded up $0.01 during trading hours on Wednesday, hitting $90.33. The company’s stock had a trading volume of 694,054 shares, compared to its average volume of 1,470,209. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $98.82. The business has a 50 day moving average price of $85.39 and a two-hundred day moving average price of $65.41. The company has a market cap of $10.91 billion, a PE ratio of -23.83 and a beta of 1.37.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Analysts expect that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently bought and sold shares of the stock. RiverPark Advisors LLC purchased a new position in shares of Natera during the fourth quarter valued at about $27,000. Principal Securities Inc. bought a new stake in shares of Natera during the fourth quarter worth $32,000. Oliver Lagore Vanvalin Investment Group lifted its holdings in shares of Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after buying an additional 389 shares during the period. Harvest Fund Management Co. Ltd purchased a new stake in shares of Natera in the 3rd quarter worth approximately $44,000. Finally, CWM LLC lifted its stake in shares of Natera by 224.4% during the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after purchasing an additional 911 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Piper Sandler upped their price target on Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. The Goldman Sachs Group upped their target price on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a research note on Friday, April 5th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. Finally, Craig Hallum started coverage on shares of Natera in a research report on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. One research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.